Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cindilizumab plus chemotherapy followed by surgery for oligometastatic esophageal squamous cell carcinoma
ChiCTR2500108825Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) (3 cohorts), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Median overall survival. Started Sep 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500108825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108825.